FDA-Approved EchoNext Flags 4 Heart Risks Free via OpenEvidence
Updated
Updated · The New York Times · Jun 22
FDA-Approved EchoNext Flags 4 Heart Risks Free via OpenEvidence
3 articles · Updated · The New York Times · Jun 22
Summary
OpenEvidence will offer EchoNext free to doctors who upload an ECG, marking the chatbot’s first integrated AI diagnostic tool after the model won FDA clearance.
EchoNext reads ECGs in under 10 minutes and flags poor pumping, valve damage, thickened heart walls and pulmonary hypertension—patterns clinicians can miss in busy settings.
At NewYork-Presbyterian, the tool helped catch a 45-year-old man’s severe heart failure after an ER visit initially ended with asthma treatment; follow-up testing found his heart was ejecting just 10% of blood per beat.
That case, published in Nature Medicine, ended in a heart transplant after genetic testing found a rare disorder linked to sudden death.
With about half of U.S. doctors already using OpenEvidence, the rollout could push validated cardiac AI beyond major academic centers where such tools have largely remained confined.
As AI diagnoses become more accurate than doctors', what is the new primary role for physicians?
If a life-saving AI makes a fatal error, who is legally held accountable?
AI-Driven ECG Screening: EchoNext’s Immediate Impact and the Future of Cardiovascular Diagnostics
Overview
EchoNext’s regulatory clearance in June 2026 marks a major shift in heart disease screening, as artificial intelligence now plays a key role in early detection. By using advanced AI to analyze standard ECGs—which are already inexpensive, noninvasive, and widely used—EchoNext can find heart diseases that cardiologists might miss during routine care. This breakthrough is driving adoption across healthcare settings and signals a broader transformation in how clinicians approach cardiovascular screening, moving from traditional, symptom-driven methods to proactive, AI-powered early detection that can benefit millions of patients.